Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Short term Debt (2016 - 2017)

Lisata Therapeutics' Short term Debt history spans 8 years, with the latest figure at $450315.0 for Q2 2017.

  • For Q2 2017, Short term Debt fell 91.01% year-over-year to $450315.0; the TTM value through Jun 2017 reached $450315.0, down 91.01%, while the annual FY2016 figure was $3.1 million, 25.05% down from the prior year.
  • Short term Debt reached $450315.0 in Q2 2017 per LSTA's latest filing, down from $3.2 million in the prior quarter.
  • In the past five years, Short term Debt ranged from a high of $5.0 million in Q2 2016 to a low of $23175.0 in Q1 2014.
  • Average Short term Debt over 5 years is $2.2 million, with a median of $2.3 million recorded in 2016.
  • Peak YoY movement for Short term Debt: plummeted 99.32% in 2014, then soared 9578.41% in 2015.
  • A 5-year view of Short term Debt shows it stood at $213112.0 in 2013, then soared by 420.67% to $1.1 million in 2014, then skyrocketed by 275.94% to $4.2 million in 2015, then decreased by 25.05% to $3.1 million in 2016, then tumbled by 85.6% to $450315.0 in 2017.
  • Per Business Quant, the three most recent readings for LSTA's Short term Debt are $450315.0 (Q2 2017), $3.2 million (Q1 2017), and $3.1 million (Q4 2016).